Metastatic urothelial carcinoma: Is addition of more therapies to treatment regimens beneficial?

Shilpa Gupta, MD, discusses several recent studies in the metastatic urothelial carcinoma space.

In this video, Shilpa Gupta, MD, discusses how recent research appears to indicate that the addition of more agents is not beneficial to patients undergoing treatment for metastatic urothelial carcinoma. Gupta is the Director of the Genitourinary Medical Oncology at Taussig Cancer Institute and Co-Leader of the Genitourinary Oncology Program at Cleveland Clinic.